Midodrine is an alpha-adrenergic agonist used to treat orthostatic hypotension. An ethanolamine derivative that is an adrenergic alpha agonist.
- Mechanism
- Curator reviewed
Midodrine undergoes metabolism to form its pharmacologically active metabolite, desglymidodrine. Desglymidodrine acts as an agonist at the alpha1-adrenergic receptors expressed in the arteriolar and venous vasculature. Activation of alpha1-adrenergic receptor signaling pathways lead to an increase in the vascular tone and elevation of blood pressure. Desglymidodrine is reported to have negligible effect on the cardiac beta-adrenergic receptors.
- Primary indication
- For the treatment of symptomatic orthostatic hypotension (OH).Curator reviewed · 1 structured indication
- Formula / weight
- C12H18N2O4 · 254.2823 g/mol (avg)
- First approval
- Canada, 2008 · United States, 1996
- Also known as
- Midodrin
- Code names
- ST-1085
- Brand names
Resolves to
PTKSEFOSCHHMPD-UHFFFAOYSA-NSMILESCOC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Midodrine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account